Regeneron's immune disorder therapy improves daily functions in trial – Reuters
- Regeneron’s immune disorder therapy improves daily functions in trial Reuters
- Regeneron’s rare immune disorder therapy meets main goal of late-stage trial Reuters
- Regeneron plots 2026 FDA filing after Phase III win in myasthenia gravis FirstWord Pharma
- 2.3-Point MG-ADL Score Improvement: Regeneron’s Quarterly gMG Drug Outperforms Current Treatments in Phase 3 Stock Titan
- RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial BioPharma Dive